NCT04240821View on ClinicalTrials.gov

Theophylline for Treatment of Pseudohypoparathyroidism

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
PseudohypoparathyroidismPseudohypoparathyroidism Type 1aAlbright Hereditary Osteodystrophy
Interventions
DRUG

Theophylline ER

Oral theophylline

Trial Locations (1)

37212

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Ashley Shoemaker

OTHER